fto

UUN44923 is a FTO inhibitor. It may be useful for treating diseases assocd. with FTO targets, obesity, metabolic syndrome (MS) , type 2 diabetes (T2D) , Alzheimer's diseases, breast cancers, small- cell lung cancers, a human bone marrow striated muscle cancer, a pancreatic cancer, malignant glioblastoma and the like.

FTO-IN-3, a FTO inhibitor, impairs self-renewal in glioblastoma stem cells (GSCs).

FTO-IN-5 is a potent, selective inhibitor targeting the fat mass obesity-associated protein (FTO).

FTO-IN-7d is the first inhibitor of the RNA demethylase FTO with anticonvulsant activity.

FTO-IN-4 is a potent and selective inhibitor of the adiposity and obesity-associated protein (FTO).

FTO-IN-8, also known as FTO-43, is an inhibitor of N6-methyladenosine demethylase FTO (fat mass- and obesity-associated protein). It exhibits an IC50 value of 5.5 μM and displays anti-cancer cell proliferative activity [1].

FTO-IN-6 is a selective inhibitor of the fat mass and obesity-associated protein (FTO).

FTO-IN-2, a FTO inhibitor, impairs self-renewal in glioblastoma stem cells.

FTO-IN-1 TFA is an inhibitor of adiposity and obesity-related enzymes (FTO) (IC50 < 1 μM).FTO-IN-1 TFA can be used to study cancer.

FTO-IN-10 (compound 7), a potent inhibitor of the human demethylase FTO (fat mass and obesity-associated protein), exhibits an IC50 of 4.5 μM. It interacts with the binding pocket of FTO's structural domain II via hydrophobic and hydrogen bonding interactions, and promotes DNA damage and autophagic cell death in A549 cells [1].

Ceftobiprole (Ro 63-9141) is a broad-spectrum cephalosporin effective against Methicillin-resistant Staphylococcus aureus (MRSA; MIC90: 2 μg mL).

Elexacaftor (VX-445) is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR) and it also facilitates the processing and trafficking of CFTR to increase the amount of CFTR at the cell surface.

Lumacaftor (VRT 826809) is a CFTR modulator that corrects the folding and trafficking of CFTR protein. It enhances F508del-CFTR protein maturation in FRT cells (EC50: 100 nM).

Naftopidil (KT-611) (INN, marketed under the brand name Flivas), an antihypertensive medicine, is used as a selective α1-adrenergic receptor antagonist or α-blocker.

Ivacaftor (VX-770) (VX-770) is a potentiator of CFTR targeting G551D-CFTR (EC50: 100 nM) and F508del-CFTR (EC50: 25 nM) in Fisher rat thyroid cells, respectively.

Aminaftone, a derivative of 4-aminobenzoic acid, inhibits endothelin-1 (ET-1) production and is used to study hypertension and systemic sclerosis.

Bonafton (Bonaphthone) is an antiviral agent.

Bamocaftor is a CFTR channel (DeltaF508-CFTR mutation) corrector for CF transmembrane conductance regulators designed to restore F508del-CFTR protein function. Combined use of tezacaftor and VX-561 for the treatment of cystic fibrosis patients with F508del/MF.

Schaftoside (APIGENIN-6-GLUCOSIDE-8-ARABINOSIDE) has antioxidant and anticancer activity.

Tezacaftor (VX661) is a small molecule that can be used as a corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) gene function.

Entacapone (OR-611) is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT).

Lisaftoclax (Bcl-2/Bcl-xl inhibitor 1) is an oral dual inhibitor of Bcl-2 and Bcl-xl, with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. Lisaftoclax is used to treat chronic lymphocytic leukemia (CLL) by inhibiting the action of the BCL-2 protein, which promotes the death of leukemia cells.

Ceftobiprole medocaril (BAL5788), the parenteral prodrug of Ceftobiprole, is a broad-spectrum cephalosporin effective against Methicillin-resistant Staphylococcus aureus (MRSA).

Icenticaftor (QBW251) is an orally active potentiator of the CFTR channel.

Nesolicaftor (PTI-428) specifically enhances cystic fibrosis transmembrane conductance regulator protein synthesis.

Isoschaftoside is used as an intercrop due to its allelopathic inhibition of parasitism by Striga hermonthica, an obligate parasitic weed that can devastate the maize crop. Isoschaftoside has anti-tumor, antioxidant, and antimicrobial activities, it also possesses strong nematicidal activity against M. incognita.

Clausine E is an inhibitor of fat mass and obesity-associated protein (FTO) demethylase activity. The binding of Clausine E to FTO was driven by positive entropy and negative enthalpy changes.

MUN36378 is a FTO inhibitor for treatment of leukemia.

Tezacaftor-d4 is a deuterated compound of Tezacaftor. Tezacaftor has a CAS number of 1152311-62-0. VX-661 is a small molecule that can be used as a corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) gene function.

Ivacaftor hydrate is an orally bioavailable CFTR potentiator. It also is used for cystic fibrosis treatment.

(R)-Elexacaftor, an enantiomer of Elexacaftor, functions as a modulator of the cystic fibrosis transmembrane conductance regulator (CFTR). It exhibits an EC50 of 0.29 µM for the CFTR dF508 mutation [1].

(Rac)-Tezacaftor ((Rac)-VX-661) is a racemic mixture of the F508del CFTR corrector, Tezacaftor, used in cystic fibrosis research [1].

Ceftolozane Sulfate may be used to treat urinary tract infections.

CTP-656, a cystic fibrosis transmembrane conductance regulator (CFTR) channel activator, is used potentially for the treatment of cystic fibrosis.

Navocaftor, as a cystic fibrosis transmembrane regulator ( CFTR ), is a protein modulator (US 20200377491 Al, example 1).

Naftopidil dihydrochloride (KT-611 2HCl) is a selective 5-HT1A and α1-adrenergic receptor antagonist with IC50 of 0.1 μM and 0.2 μM, respectively.

Ceftobiprole medocaril sodium (BAL5788) is a parenteral prodrug of Ceftobiprole, a pyrrolidinone cephalosporin administered intravenously. As a broad-spectrum cephalosporin, Ceftobiprole exhibits high in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococci (VRSA), and penicillin-resistant Streptococci. Additionally, it is effective in inhibiting both gram-positive and gram-negative pathogens.

Zatonacaftor, a cystic fibrosis transmembrane regulator (CFTR) modulator, is utilized in the research of cystic fibrosis [1] [2].

Aftobetin, also known as ANCA11 and NCE-11, is a novel amyloid–binding compound applied topically in the form of an ophthalmic ointment. Aftobetin may be of useful as an aid in the diagnosis Alzheimer's disease.

(R)-Vanzacaftor ((R)-VX-121) is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator [1].

Naftoxate is an antimicotic. It is effective against both gram-positive and gram-negative bacteria as well as yeasts and other fungi in plant cell culture.

(R)-Olacaftor ((R)-VX-440), a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator, demonstrates promising potential in cystic fibrosis (CF) research.

Ceftolozane, also known as FR-264,205 and CXA-101; is an antibiotic drug from the cephalosporin family, approved for the treatment of infections with gram-negative bacteria, or gram-positive bacteria. Ceftolozane is of great benefit due to its ability to target bacteria that have become resistant to conventional antibiotics. Ceftolozane is combined with the β-lactamase inhibitor tazobactam, as multi-drug resistant bacterial infections will generally show resistance to all β-lactam antibiotics unless this enzyme is inhibited. .

(R)-Posenacaftor ((R)-PTI-801) sodium, the R enantiomer of Posenacaftor, is a cystic fibrosis transmembrane regulator (CFTR) protein modulator. It corrects the folding and trafficking of the CFTR protein, and is utilized in the research of cystic fibrosis (CF)[1].

Dirocaftor (PTI-808) is a CFTR potentiator that enhances CFTR protein function by activating chloride channels, with potential utility for cystic fibrosis (CF) research.

Neoschaftoside has antioxidant activity.

Naftopidil hydrochloride (BM-15275 hydrochloride) is a selective alpha1-adrenoceptor antagonist with Ki of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-adrenoceptor, α1b-adrenoceptor and α1d-adrenoceptor, respectively. Naftopidil hydrochloride has antiproliferative effects.

Aftobetin is a biochemical.

(Rac)-Lisaftoclax ((Rac)-APG-2575), a Bcl-2 inhibitor, is utilized in hematologic malignancy research (CN112898295A) [1].

Ziftomenib (KO-539) is an inhibitor of menin-MLL interaction with antitumor activity, suitable for leukemia research.